Mannkind Corporation Stock Prediction
AI-powered sentiment analysis and prediction trends for MNKD, updated each market day.
MNKD AI Sentiment
AI sees no strong directional signal for Mannkind Corporation stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Mannkind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Sector
Exchange
Market Cap
$1,151,129,252
Cap Tier
Employees
592
Headquarters
DANBURY, CT
Listed Since
July 28, 2004
Website
MNKD Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MNKD Volatility
Mannkind Corporation has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
